Keratinocytic pathology (BCC, SCC, actinic keratosis)

Definition & Scope

Keratinocytic pathology interprets neoplasms of epidermal keratinocytes — the bulk of “non-melanoma” / keratinocyte skin cancer practice — spanning precursors (actinic keratosis, AK), SCC in situ, invasive cutaneous SCC (cSCC), the keratoacanthoma (KA) spectrum, and basal cell carcinoma (BCC).[2][3][4] This leaf is the histology and reporting companion to clinical topics on AK, BCC, SCC, Mohs, and margins.

Field Cancerization

Chronic UV exposure produces clones of genetically altered keratinocytes across a field, not only the scaly papule you freeze.[7] Clinically this explains multiple AKs, subclinical dysplasia, and recurrent “new” lesions adjacent to treated spots. AAD guidelines frame AK management as both lesion-directed and field-directed care when burden is high.[8][9]

Sampling That Makes Pathology Useful

Technique decides whether subtype and invasion can be assessed.[3][5]

Always state on the form: site, size, clinical diagnosis/differential, prior treatment (cryo, 5-FU, imiquimod, PDT), immunosuppression, and whether margins are intended as diagnostic only. [1]

Exam application bank (NEET-PG / INICET)

One-line answer

Board-level dermatopathology leaf on keratinocytic neoplasia: actinic keratosis and field cancerization, SCC in situ (Bowen), invasive cutaneous SCC with high-risk features, keratoacanthoma spectrum, and basal cell carcinoma subtypes. Emphasises adequate sampling, report elements that change surgery (depth, PNI, subtype, margins), Ber-EP4 pitfalls, and management mapping without replacing dedicated clinical BCC/SCC topics.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Keratinocytic pathology (BCC, SCC, actinic keratosis).

Expanded exam teaching (depth pass)

Clinical reasoning

For Keratinocytic pathology (BCC, SCC, actinic keratosis), examiners test whether you can prioritise life threats, choose the right first test, and give specific therapy (agent, dose, route, timing). Generic phrases without numbers score poorly.

Mechanism → feature map

Build a short chain: cause → pathophysiologic intermediate → clinical feature → complication. Every major symptom in the classic vignette should sit on that chain.

Investigation strategy

• Bedside/first-line tests that change immediate management
• Confirmatory or staging tests
• What a normal result does not exclude
• When not to delay treatment for imaging (unstable patient)

Management ladder

1. Resuscitation / ABC / sepsis or haemorrhage bundle as relevant
2. Specific antidote / procedure / antimicrobial / reperfusion / surgery
3. Supportive care and monitoring targets
4. Definitive long-term therapy and secondary prevention
5. Disposition and safety-net advice

Special populations

Always prepare one line each for children, pregnancy, elderly, renal/hepatic impairment, and immunocompromised patients when the topic allows.

Pitfalls that fail candidates

• Treating the number not the patient
• Missing pregnancy status when relevant
• Imaging before stabilisation
• Wrong empiric cover or wrong antidote timing
• Incomplete counselling on recurrence, adherence, or red-flag return

Board-level dermatopathology leaf on keratinocytic neoplasia: actinic keratosis and field cancerization, SCC in situ (Bowen), invasive cutaneous SCC with high-risk features, keratoacanthoma spectrum, and basal cell carcinoma subtypes. Emphasises adequate sampling, report elements that change surgery (depth, PNI, subtype, margins), Ber-EP4 pitfalls, and management mapping without replacing dedicated clinical BCC/SCC topics. [1]

Structured revision sheet

Must-know numbers and names

List every score, size threshold, dose, and time window from this topic on a blank page from memory, then check against the sections above.

Three classic MCQ angles

1. Most likely diagnosis given a vignette
2. Next best step in management
3. Most appropriate investigation

Three classic SAQ angles

1. Pathophysiology in five steps
2. Management algorithm with doses
3. Complications and prevention

Clinical station flow

Greet → focused history → targeted exam → investigations → explain diagnosis → emergency care → definitive plan → safety-net / follow-up → answer examiner questions on mechanism and pitfalls.

[1]

Actinic Keratosis — Histology Essentials

Classic teaching set:[8][9]

• Partial-thickness keratinocyte atypia (basal and lower spinous layers more than full epidermis)
• Alternating ortho- and parakeratosis (“flag sign” teaching image)
• Solar elastosis in the dermis
• Sparing of adnexal epithelium in some patterns (helpful teaching pearl, not absolute) [1]

When atypia becomes full-thickness, language shifts toward SCC in situ. Borders are continuous in real life — clinicopathologic correlation prevents false comfort. [1]

SCC in Situ (Bowen Disease) & Invasive SCC

SCC in situ

Full-thickness epidermal keratinocyte atypia without invasion through the basement membrane. May be UV-related on sun-exposed skin or HPV-related in anogenital sites — site history matters for work-up framing.[4][6]

Invasive cutaneous SCC

Invasion into dermis (or deeper) defines invasive disease. Contemporary reviews emphasise incidence, risk factors, diagnosis, and staging elements that pathologists and clinicians share.[3][4][5][6]

High-yield report elements (exam list): [1]

Keratoacanthoma Spectrum

KA presents as a rapidly growing crateriform nodule; histology shows a well-differentiated crateriform keratinocytic proliferation that can closely mimic well-differentiated SCC.[12] Board stance: many centres manage KA-like lesions with complete excision and path review rather than assuming spontaneous resolution — especially in adults and immunosuppressed patients.[12][4]

Basal Cell Carcinoma — Subtype Is Destiny

BCC is the commonest keratinocyte carcinoma clinically; European interdisciplinary guidance and clinical reviews stress diagnosis, subtype, and treatment selection.[1][2]

Classic nodular BCC histology

• Basaloid nests of varying size
• Peripheral palisading
• Retraction artefact (stromal clefting)
• Mucinous stroma in many cases [1]

Why subtype must be reported

Immunohistochemistry — Support, Not Magic

Ber-EP4 classically labels BCC and helps separate BCC from SCC in ambiguous nests.[10] Limitations matter on boards: Bowen disease can show Ber-EP4 reactivity, so morphology and the full panel context still rule.[11] EMA, high-molecular-weight keratins, and p63/p40 enter selected adnexal and spindle differentials — never as a lone “SCC stain” without architecture.

Differentials That Catch Candidates

From Report to Management Algorithm

[1]

Mapping (principles, not a dose table)

• AK: lesion- and field-directed options per AAD guidance; photoprotection always.[8][9]
• SCCIS: complete destruction/excision with clinical margin discipline — do not leave untreated full-thickness atypia on critical sites.
• Invasive SCC: surgery with risk-adapted margins; high-risk features → specialist/MDT.[3][4][5]
• BCC: low-risk nodular/superficial pathways vs high-risk infiltrative/micronodular → Mohs or careful margin control per European consensus framing.[1][2]

Regional & Exam Notes

MBBS/NEET-PG expect the spectrum table and red flags. MRCP/IADVL add transplant SCC risk and field cancerization. FACD/FRCDerm/ABD push subtype language, PNI reporting, Ber-EP4 limits, and Mohs indications. Skin of colour: pigmented BCC and under-recognised AK on non-classic sites need deliberate exam. [1]

Bottom Line

Report keratinocytic lesions so a surgeon can act: how thick is the atypia, has it invaded, what is the subtype, are nerves involved, and are margins free? Architecture first; stains second; clinical field and host always in the room.[1][4][7][10]

References

1. [1]Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 Eur J Cancer, 2023.PMID 37604067
2. [2]Heath MS, Bar A. Basal Cell Carcinoma Dermatol Clin, 2023.PMID 36410973
3. [3]Waldman A, Schmults C. Cutaneous Squamous Cell Carcinoma Hematol Oncol Clin North Am, 2019.PMID 30497667
4. [4]Wysong A. Squamous-Cell Carcinoma of the Skin N Engl J Med, 2023.PMID 37314707
5. [5]Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging J Am Acad Dermatol, 2018.PMID 29332704
6. [6]Jiang R, Fritz M, Que SKT. Cutaneous Squamous Cell Carcinoma: An Updated Review Cancers (Basel), 2024.PMID 38791879
7. [7]Willenbrink TJ, Ruiz ES, Cornejo CM, et al. Field cancerization: Definition, epidemiology, risk factors, and outcomes J Am Acad Dermatol, 2020.PMID 32387665
8. [8]Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis: Executive summary J Am Acad Dermatol, 2021.PMID 34111497
9. [9]Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis J Am Acad Dermatol, 2021.PMID 33820677
10. [10]Tellechea O, Reis JP, Domingues JC, et al. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin Am J Dermatopathol, 1993.PMID 8238781
11. [11]Kogut M, Toberer F, Enk AH, et al. Limitations of Ber-EP4 for distinction of Bowen disease from basal cell carcinoma J Cutan Pathol, 2016.PMID 26765054
12. [12]Bahmad HF, Stoyanov K, Mendez T, et al. Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers Dermatopathology (Basel), 2024.PMID 39449378